Showing 5311-5320 of 8887 results for "".
- Analysis Highlights Factors Affecting Long-term Antibiotic Prescriptions for Acnehttps://practicaldermatology.com/news/analysis-highlights-factors-affecting-long-term-antibiotic-prescriptions-acne/2462633/A new analysis provided insight into the thinking of dermatologists prescribing antibiotics for treating acne. The research team set out to identify factors influencing prolonged oral antibiotic prescriptions for acne treatment by dermatologists, despite guidelines recommending limitation
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatm
- Meta-analysis: Omalizumab Alleviates Psychiatric Comorbidities of Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/meta-analysis-omalizumab-alleviates-psychiatric-comorbidities-chronic-spontaneous-urticaria/2462572/A new review suggests that omalizumab was associated with a reduction in psychiatric cormidities in a number of different studies and settings. The systematic review and meta-analysis sourght to assess the clinical impacts of omalizumab on depression, anxiety, and sleep disturbances in p
- Rosacea Awareness Month: Society Highlights Challenges of Disruptive Disorderhttps://practicaldermatology.com/news/rosacea-awareness-month-society-highlights-challenges-disruptive-disorder/2462552/April is designated as National Rosacea Awareness Month, and the National Rosacea Society (NRS) is taking steps to highlight the unique challenges that milli
- Study Validates Thermal Imaging, ALT-70 Model for Distinguishing Cellulitis from Pseudocellulitishttps://practicaldermatology.com/news/study-validates-thermal-imaging-alt-70-model-distinguishing-cellulitis-pseudocellulitis/2462541/A new diagnostic validation study in JAMA Dermatology has shed light on the potential of surface thermal imaging and the ALT-70 (asymmetry, leukocytosis, tachycardia, and age ≥70 years) prediction model in differentiating cellulitis from pseudocellulitis. "Cellulitis is misdiagno
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- Integrated Dermatology Appoints Tushar Ramani, MD, as CEOhttps://practicaldermatology.com/news/integrated-dermatology-appoints-tushar-ramani-md-ceo/2462493/Integrated Dermatology has announced the appointment of Tushar Ramani, MD, as the company's new chief executive officer (CEO). Dr. Ramani will be replacing Jeff Queen, who after two decades as CEO and executive chairman, is transitioning to the role of co-executive chairman of the Board alongside
- Updated Coding Curbs Complex Repair Billing by Mohs Surgeonshttps://practicaldermatology.com/news/updated-coding-curbs-complex-repair-billing-mohs-surgeons/2462489/Complex repairs billed by Mohs surgeons decreased significantly from 2019 to 2021 in the wake of new coding guidelines, according to a national Medicare analysis. Publishing in Dermatologic Surgery, Christian Gronbeck, MD, of the University of Connecticut, Farmington, and colleag
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- Review: Lack of Specificity Seen in Outcome Measurement Instruments Used for AE Reporting in Cancer Trialshttps://practicaldermatology.com/news/outcome-measurement-instruments-used-to-evaluate-dermatologic-adverse-events-in-cancer-trials/2462443/Some common measurement instruments of patient-reported outcomes in skin cancer trials lack specificity and rigorous validation, according to a new systematic review. "Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated